Panbela Therapeutics Total Liabilities and Share Holders Equity 2020-2024 | PBLA

Panbela Therapeutics total liabilities and share holders equity from 2020 to 2024. Total liabilities and share holders equity can be defined as the total of all liabilities and shareholders' equity.

Panbela Therapeutics Total Liabilities and Share Holders Equity 2020-2024 | PBLA

Panbela Therapeutics total liabilities and share holders equity from 2020 to 2024. Total liabilities and share holders equity can be defined as the total of all liabilities and shareholders' equity.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$141.5B
Gilead Sciences (GILD)$117.7B
Bristol Myers Squibb (BMY)$117.6B
Vertex Pharmaceuticals (VRTX)$105.8B
CSL (CSLLY)$85.8B
Regeneron Pharmaceuticals (REGN)$78.8B
GSK (GSK)$70.7B
Argenex SE (ARGX)$38.2B
Alnylam Pharmaceuticals (ALNY)$31.3B
BioNTech SE (BNTX)$27.3B
Biogen (BIIB)$21.8B
Illumina (ILMN)$21.4B
BeiGene (BGNE)$18B
Moderna (MRNA)$15.6B
Genmab (GMAB)$13.6B
Incyte (INCY)$13.4B
BioMarin Pharmaceutical (BMRN)$12.8B
Insmed (INSM)$12.6B
Sarepta Therapeutics (SRPT)$11.8B
Bio-Techne Corp (TECH)$11.6B
Vaxcyte (PCVX)$10.7B
Exact Sciences (EXAS)$10.6B
QIAGEN (QGEN)$10.3B
Swedish Orphan Biovitrum (BIOVF)$9.8B
Exelixis (EXEL)$9.7B
Bio-Rad Laboratories (BIO.B)$9.1B
Intra-Cellular Therapies (ITCI)$9.1B
Roivant Sciences (ROIV)$8.7B
Ascendis Pharma (ASND)$8.5B
Repligen (RGEN)$8.2B